(Q57988219)

https://api.crossref.org/works/10.1038%2FNRMICRO2893

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structure-based antigen design: a strategy for next generation vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Rational design of a meningococcal antigen inducing broad protective immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Vaccine potential of the Neisseria meningitidis 2086 lipoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

A universal vaccine for serogroup B meningococcus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structural Basis for the Immunogenic Properties of the Meningococcal Vaccine Candidate LP2086

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Solution Structure of the Factor H-binding Protein, a Survival Factor and Protective Antigen of Neisseria meningitidis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Complement-mediated bactericidal activity of anti-factor H binding protein monoclonal antibodies against the meningococcus relies upon blocking factor H binding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Epitope mapping of a bactericidal monoclonal antibody against the factor H binding protein of Neisseria meningitidis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Design of meningococcal factor H binding protein mutant vaccines that do not bind human complement factor H.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Bactericidal antibody responses induced by meningococcal recombinant chimeric factor H-binding protein vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Group B streptococcal disease in infants aged younger than 3 months: systematic review and meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Level of maternal IgG anti-group B streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Genome Analysis Reveals Pili in Group B Streptococcus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Pili in gram-positive pathogens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structure of Respiratory Syncytial Virus Fusion Glycoprotein in the Postfusion Conformation Reveals Preservation of Neutralizing Epitopes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structural basis of respiratory syncytial virus neutralization by motavizumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structure of a Major Antigenic Site on the Respiratory Syncytial Virus Fusion Glycoprotein in Complex with Neutralizing Antibody 101F

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Conformational constraints of conserved neutralizing epitopes from a major antigenic area of human respiratory syncytial virus fusion glycoprotein.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Conformational studies of a short linear peptide corresponding to a major conserved neutralizing epitope of human respiratory syncytial virus fusion glycoprotein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Design and Characterization of Epitope-Scaffold Immunogens That Present the Motavizumab Epitope from Respiratory Syncytial Virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structural and genetic basis for development of broadly neutralizing influenza antibodies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Antibody recognition of a highly conserved influenza virus epitope

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Influenza virus vaccine based on the conserved hemagglutinin stalk domain

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

Design and Evaluation of Meningococcal Vaccines through Structure-Based Modification of Host and Pathogen Molecules

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRMICRO2893

A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23154260